Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law

The US Health and Human Services Department is authorized to ‘negotiate’ drug prices in Medicare for the first time in newly-enacted legislation. But the law lacks a clear framework for the process, leaving many key aspects to HHS.

That offers manufacturers an opportunity to shape the policy but also creates significant uncertainty about the ultimate impact of the program. The Centers for Medicare and Medicaid Services has a...